Researchers have developed a new oral medication called aleniglipron that may help people with obesity or overweight lose significant weight. In a recent clinical trial, participants taking this small-molecule drug lost as much as 12.1% of their body weight over 36 weeks. Unlike existing GLP-1 treatments like Wegovy and Ozempic, which require injections, aleniglipron can be taken once daily with or without food, making it a more accessible option for many.

This finding is particularly relevant for individuals seeking effective weight management solutions. With obesity linked to numerous health issues, including heart disease and diabetes, a medication that promotes weight loss could lead to improved overall health and longevity. In the trial involving 230 adults, those taking the highest dose of aleniglipron experienced an average weight loss of 12.1%, compared to just 0.5% in the placebo group. This substantial difference highlights the potential of aleniglipron as a viable treatment option for weight loss.

The evidence comes from a phase II clinical trial, which is an early-stage study designed to assess the drug’s safety and effectiveness. While the results are promising, further research in a phase III trial will be necessary to confirm these findings and explore the long-term effects of aleniglipron. Researchers noted that gastrointestinal side effects were generally mild and lessened over time, indicating that the drug may be well-tolerated by users.

As this research progresses, those interested in weight management should stay informed about new treatment options like aleniglipron, which could offer a more convenient and effective way to achieve their health goals.

Source: Northwestern Medicine